Advertisement
Loading...

ImmuCell Corporation

ICCC•NASDAQ
Healthcare
Biotechnology
$10.50
$0.38(3.75%)
U.S. Market opens in 7h 50m
Advertisement

ImmuCell Corporation (ICCC) Stock Overview

Explore ImmuCell Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap95M
P/E Ratio-174.73
EPS (TTM)$-0.07
ROE-0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$10.25
3 Months$9.27
1 Year Target$8.19

ICCC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmuCell Corporation (ICCC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 75.32, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $8.19.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -174.73 and a market capitalization of 95M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
3.75%
5-Day Change
7.14%
1-Month Change
25.60%
3-Month Change
60.31%
6-Month Change
118.75%
Year-to-Date (YTD) Change
70.73%
1-Year Change
68.00%
3-Year Change
96.26%
5-Year Change
10.53%
All-Time (Max) Change
11.94%

Contact Information

https://immucell.com
207 878 2770
56 Evergreen Drive, Portland, ME, 04103

Company Facts

69 Employees
IPO DateMay 5, 1987
CountryUS
Actively Trading

Frequently Asked Questions